Financing Momentum Peptomyc has recently secured significant equity financing totaling around €5 million in early 2026, signaling strong investor confidence and potential appetite for partnership discussions to accelerate clinical development of OMO-103.

Clinical Progress With a Phase 2 trial approval for OMO-103 in both pediatric and adult osteosarcoma, there is a clear near-term clinical milestone trajectory that could open opportunities for sponsorships, co-development, or milestone-based collaborations around MYC-targeted therapeutics.

Leadership Credentials Strategic leadership appointments, including a new Board Chair and a Board member with pharma biotech experience, enhance Peptomyc’s credibility for potential licensing deals, strategic partnerships, or advisory collaborations to de-risk and accelerate development programs.

Specialized Focus Positioning around MYC-focused mini-protein therapeutics and direct MYC inhibition aligns with a niche but high-need oncology space, presenting opportunities for collaboration with CROs, contract manufacturing, or custom peptide/mini-protein development partners.

Funding Readiness A reported revenue range near zero to one million alongside active fundraising and a track record of equity rounds suggests Peptomyc may be receptive to strategic investments, licensing options, or milestone-driven partnerships to advance clinical milestones and scale manufacturing.